Interview with Pavel Chistyakov, General Manager, Pierre Fabre Russia
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
Address: 119435 г.Москва, Саввинская набережная, д. 11,Russia
Tel: +7 (495) 789 9533
Web: http://www.pierre-fabre-Russia.ru/
Today, almost half a century since its founding, the Pierre Fabre Group is the second largest private pharmaceutical company in France and has market presence in over 140 countries around the world. Business within the company’s Russian affiliate is beginning to evolve rapidly. In 1993, the first drug produced by Pierre Fabre appeared on the Russian market. In 1999, the Group began selling skin care products through its exclusive distributor. In 2008, the decision was made to merge all areas in Russia, and in 2009, the company opened a 100% Russian subsidiary. In May 2009, the first skin care products were delivered to the affiliate from France, and in 2010, the first dental products were delivered.
In Russia, the main activity of LLC Pierre Fabre is the promotion of skin cosmetics, which are divided in two areas: dermatology and aesthetic skin care.
Pierre Fabre’s skin care products are sold exclusively in pharmacies.
Dermo-cosmetics and pharmaceutical products
You were responsible for merging Pierre Fabre’s activities in Russia in 2008, and heading the new legal entity and 100% subsidiary. What is it like to set up a new…
IMEDA was founded in 2005, and today counts amongst its members 28 leading international companies in the Russian medical technology sector. What are the main goals of the association today,…
When we first met, you mentioned that you assumed this position in 2009, to help UCB Russia recover from a flat spin in the wake of the financial crisis. What…
Merck KGaA describes itself as the world’s oldest pharmaceutical and chemicals company. What is the company’s history here in Russia? The Russian subsidiary was actually incorporated over 100 years ago.…
Ipsen has recently announced the acquisition of a Russian pharmaceutical license. Even before this license, Russia was already one of the largest affiliates. of the group, as of 2010. The…
What were the difficulties in the CIS regions around the time of the financial crisis? Were there similarities to the situation in Russia? Yes, the situation in the CIS was…
You have been with Boehringer Ingelheim since the early days of your career in 1994. In the pharmaceutical sector, managers seem to jump from company to company quite often—but you…
You were the former director of RMBC, which was acquired in 2008 by the IMS. How important was this acquisition in terms of positioning the IMS on the Russian market?…
Roche is the leading company in the ONLS (high-technology reimbursement) segment of the prescription drug market, and also the top oncology company in Russia. As the General Manager of the…
You have been in Russia now for a bit less than a year, having come from the former Schering-Plough’s Hungary office to run the Russian MSD affiliate. In our conversation…
Binnopharm was established in 2006, with 100% of charter capital coming from holding company JSFC Sistema. What was the vision behind the creation of Binnopharm? The company was indeed established…
Nycomed is currently constructing a Greenfield plant in the Yaroslavl region, at an investment of 75-80Mn EUR. Last time we met in 2006, many foreign companies viewed local production as…
Celegene did not have a Russian affiliate office during Focus Reports’ initial report on Russia in 2006. What attracted Celgene’s relatively recent entrance into this market? We had external and…
See our Cookie Privacy Policy Here